Venetoclax

BreastfeedingPediatric
  • TRADE NAME: Venclexta (AbbVie)
  • INDICATIONS: Chronic lymphocytic leukemia in patients with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy
  • CLASS: BCL-2 inhibitor
  • HALF-LIFE: 26 hours

FDA APPROVAL DATE: 04/11/2016

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Amiodarone, Azithromycin, Bosentan, Captopril, Carbamazepine, Carvedilol, Ciprofloxacin, Clarithromycin, Conivaptan, Cyclosporine, Digoxin, Diltiazem, Dronedarone, Efavirenz, Erythromycin, Etravirine, Everolimus, Felodipine, Fluconazole, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Live vaccines, Lopinavir, Modafinil, Nafcillin, Phenytoin, Posaconazole, Quercetin, Quinidine, Ranolazine, Rifampin, Ritonavir, Sirolimus, St John's Wort, Stong or moderate P-gp inhibitors or substrates, Strong or moderate CYP3A inducers or inhibitors, Telaprevir, Ticagrelor, Verapamil, Voriconazole

PREGNANCY CATEGORY: N/A
May cause fetal harm

Concomitant use of strong CYP3A inhibitors during initiation and ramp-up phase is contra-indicated.

Our database has 34 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
HEMATOLOGIC
NEUROMUSCULAR/SKELETAL
RENAL
RESPIRATORY
OTHER


Page last updated 03/07/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric